Sahajanand Medical Technologies IPO: From Issue Details to Financials; Here’s What You Need to Know
India’s medical technology sector is expanding with rising demand for advanced healthcare solutions, increasing cardiovascular procedures and greater adoption of innovative medical devices. Companies developing specialised products and strengthening their presence in international markets are positioning themselves to participate in this evolving healthcare landscape.
Against this backdrop, Sahajanand Medical Technologies is launching its Rs. 475.48 crore IPO through an offer for sale. With a presence in 77 countries, a portfolio of cardiovascular devices and improving profitability in FY26, investors may assess its financial performance, competitive strengths and business risks before evaluating the issue.
Also Read: Sensex & Nifty 50 | Stock Market Live Updates Today: Sensex Falls 250 Points, Nifty Slips Below 22,650 as Financial, Pharma Stocks Drag
IPO Key Details
Sahajanand Medical Technologies’ IPO is a book-built issue valued at Rs. 475.48 crore, consisting of an entire offer for sale (OFS) of 1.38 crore shares. As this IPO is an OFS, the funds generated by the IPO would go to the selling shareholders and the company would not get any money through the IPO.
The opening and closing dates for the IPO have been set as October 15, 2026 and October 19, 2026, respectively. Allotment is expected to be finalised on October 21, 2026, while the shares are scheduled to list on NSE & BSE on October 23, 2026. The price band is fixed at Rs. 327 to Rs. 344 per share with a lot size of 43 shares.
The minimum application by retail investors is 43 shares, which is an investment of Rs. 14,792 at the top end of the price band. The book running lead managers for the issue are Motilal Oswal Investment Advisors Ltd, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited and Nuvama Wealth Management Limited, whereas MUFG Intime India Pvt. Ltd is the registrar for the issue.
The company's shareholding will remain unchanged at 10,16,46,778 shares before and after the IPO, as the issue comprises an offer for sale entirely. Before the IPO, the promoter and promoter group hold 40.82% of Sahajanand Medical Technologies Ltd., while public shareholders own the remaining 59.18%. After the IPO, the promoter group's shareholding is expected to decrease to 36.2%, while public shareholding will increase to 63.80%, reflecting the sale of shares by existing shareholders through the Offer for Sale (OFS).
IPO Lot Size & Reservation
Investors can apply for the Sahajanand Medical Technologies IPO in a minimum lot size of 43 shares, amounting to Rs. 14,792 at the upper price band of Rs. 344 per share. Retail investors can apply for a maximum of 13 lots, comprising 559 shares, requiring an investment of Rs. 1,92,296.
For high-net-worth individual investors, the Small HNI (S-HNI) category starts at 14 lots, or 602 shares, requiring Rs. 2,07,088, and goes up to 67 lots, or 2,881 shares, amounting to Rs. 9,91,064. The Big HNI (B-HNI) category starts at 68 lots, equivalent to 2,924 shares, requiring a minimum investment of Rs. 10,05,856.
The Sahajanand Medical Technologies IPO has reserved not more than 50% of the net offer for Qualified Institutional Buyers (QIBs), not less than 35% for retail individual investors, and not less than 15% for Non-Institutional Investors (NIIs).
About the company
Sahajanand Medical Technologies Ltd, incorporated in October 2001, develops, manufactures, and markets devices used in cardiovascular surgeries. Some of its products include coronary stents, coronary balloons, TAVI devices, occluders, renal stents and peripheral drug-coated balloons. Its brand names include Supraflex Cruz, Cocoon and Hydra for different segments of interventional cardiology.
It has three manufacturing units in India and Thailand, which are complemented by R&D centers in both countries. By June 30, 2026, it had 119 patents granted worldwide, 78 patent applications pending approval and five design registrations in India. During the financial year 2026, it marketed its products in 77 countries via its direct sales, hybrid and distributor channels in India, Europe and other international markets. As of June 30, 2026, its workforce included 1,605 full-time employees, 31 consultants and 707 contract-based employees.
Financials of the company
Sahajanand Medical Technologies Ltd reported total income of Rs. 354.33 crore and a profit after tax (PAT) of Rs. 15.09 crore for the quarter ended June 30, 2026. Its EBITDA stood at Rs. 48.58 crore. For FY26, total income increased by around 18% to Rs. 1,218.73 crore from Rs. 1,035.96 crore in FY25, while PAT rose by approximately 175% to Rs. 69.08 crore from Rs. 25.15 crore. The company had reported a loss of Rs. 7.35 crore in FY24.
As of June 30, 2026, the company's total assets stood at Rs. 1,309 crore, compared with Rs. 1,276.43 crore as of March 31, 2026. Net worth increased to Rs. 631.72 crore from Rs. 616.05 crore, while reserves and surplus rose to Rs. 706.86 crore from Rs. 692.48 crore over the same period.
However, total borrowings increased to Rs. 320.63 crore as of June 30, 2026, compared with Rs. 269.53 crore in March 2026, Rs. 224.96 crore in FY25 and Rs. 175.27 crore in FY24. Investors should monitor whether the company's improving profitability and financial position can support its rising debt levels.
Objectives of the IPO
The IPO of Sahajanand Medical Technologies Ltd will be an OFS IPO only and hence the company will get no money out of this IPO because the proceeds will go into the pockets of the shareholders only. Thus, this IPO is not expected to raise any fresh funds for the company.
GMP of the IPO
Sahajanand Medical Technologies IPO’s latest recorded Grey Market Premium (GMP) stands at Rs. 43 as of October 14, 2026. With the upper price band set at Rs. 344, the estimated listing price is Rs. 387, indicating a potential listing gain of 12.50% over the issue price.
Competitive Strengths of the company
Sahajanand Medical Technologies Ltd has an advantage over others due to having a comprehensive sales and marketing network in both India and international markets. Competitive strengths for SMT include strong capability in research and development; diversified manufacturing facilities located in India and Thailand; and technology-based medical devices in specialized areas like interventional cardiology, where high entry barriers exist due to stringent regulatory and clinical requirements.
M&A experience and strategic alliances also give strength to the company as far as expansion in terms of markets and product lines is concerned. Leadership strength and renowned investors also add to the business strategy of the company.
Risks of the company
The company operates in a regulated medical devices sector and has to be compliant with the relevant regulations in all the regions where it operates. Failure to comply, changes in regulations, or any other action by the regulators may have an impact on its ability to sell its products, revenues and future expansion plans.
Also Read: Rajesh Power Services Wins ₹69 Crore UGVCL Order, Taking Two Back-to-Back Gujarat Wins to ₹540.92 Crore in a Week
The company also runs into risks relating to its manufacturing plants, which may include problems related to the quality of manufacturing, infrastructural problems and aging plant & machinery. These may result in disruption of production and higher costs of manufacture, as well as delays in delivery of its products.